39,374 Shares in Spark Therapeutics Inc (ONCE) Purchased by First Trust Advisors LP

First Trust Advisors LP bought a new stake in Spark Therapeutics Inc (NASDAQ:ONCE) in the third quarter, HoldingsChannel.com reports. The firm bought 39,374 shares of the biotechnology company’s stock, valued at approximately $2,148,000.

A number of other large investors also recently added to or reduced their stakes in ONCE. Bank of Montreal Can lifted its holdings in Spark Therapeutics by 1,045.4% during the 3rd quarter. Bank of Montreal Can now owns 3,253 shares of the biotechnology company’s stock worth $177,000 after buying an additional 2,969 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Spark Therapeutics during the 2nd quarter worth about $203,000. Cubist Systematic Strategies LLC purchased a new stake in Spark Therapeutics during the 2nd quarter worth about $268,000. NJ State Employees Deferred Compensation Plan lifted its holdings in Spark Therapeutics by 133.3% during the 3rd quarter. NJ State Employees Deferred Compensation Plan now owns 7,000 shares of the biotechnology company’s stock worth $382,000 after buying an additional 4,000 shares during the last quarter. Finally, Amalgamated Bank lifted its holdings in Spark Therapeutics by 29.7% during the 2nd quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock worth $397,000 after buying an additional 1,100 shares during the last quarter.

Spark Therapeutics stock opened at $42.13 on Friday. Spark Therapeutics Inc has a fifty-two week low of $35.63 and a fifty-two week high of $96.59. The company has a quick ratio of 10.36, a current ratio of 10.71 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $1.60 billion, a PE ratio of -5.52 and a beta of 2.27.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.04) by ($0.22). Spark Therapeutics had a negative net margin of 127.82% and a negative return on equity of 14.18%. The firm had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $27.44 million. During the same period in the previous year, the firm posted ($1.90) earnings per share. The firm’s revenue for the quarter was up 463.2% on a year-over-year basis. On average, equities research analysts expect that Spark Therapeutics Inc will post -1.47 EPS for the current year.

ONCE has been the subject of a number of recent analyst reports. ValuEngine downgraded Spark Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. UBS Group decreased their price target on Spark Therapeutics from $80.00 to $53.00 and set a “neutral” rating for the company in a report on Wednesday, August 8th. William Blair reaffirmed a “buy” rating on shares of Spark Therapeutics in a report on Friday, September 21st. Credit Suisse Group raised Spark Therapeutics from an “underperform” rating to a “neutral” rating and decreased their price target for the stock from $48.00 to $44.00 in a report on Friday, November 16th. Finally, Raymond James set a $82.00 price target on Spark Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 8th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have issued a buy rating to the company. Spark Therapeutics presently has a consensus rating of “Hold” and an average target price of $65.95.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2018/12/02/39374-shares-in-spark-therapeutics-inc-once-purchased-by-first-trust-advisors-lp.html.

Spark Therapeutics Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Featured Story: Leveraged Buyout (LBO)

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit